Spyre Prices $350M Public Offering at $85/Share, Adding $328.7M Net Proceeds
SYRE has more than doubled off its 52-week low of $15.86 on elevated volume (3.6× avg).
Summary
Spyre Therapeutics priced a $350 million public offering at $85 per share, a 4.5% discount to the October 2 closing price, raising approximately $328.7 million in net proceeds to fund its immunology pipeline through 2029.
Updates
· SEC 8-K — The 8-K confirms the underwriting agreement with Jefferies, TD Securities, Leerink Partners, and Stifel, and the offering is expected to close October 7, 2026.
Key Events · Financing and Capital Events · SYRE
-
Public Offering Priced at $85/Share
Spyre priced 4,117,648 shares at $85.00 per share, a 4.5% discount to the $93.19 last reported sale price on October 2, 2026, for total gross proceeds of $350.0 million.
-
Net Proceeds of $328.7M
After underwriting discounts of $5.10 per share ($21.0M) and estimated expenses of $350,000, Spyre will receive approximately $328.7 million, or $378.0 million if the underwriters' 617,647-share option is fully exercised.
-
Immediate Dilution of $71.51/Share
New investors face immediate dilution of $71.51 per share, as the $85.00 offering price compares to pro forma as-adjusted net tangible book value of $13.49 per share after the offering.
-
Use of Proceeds Funds Pipeline Through 2029
Proceeds will advance Gastroenterology, Rheumatology, and Dermatology programs, including Phase 3 readiness and a new SPY072 late-stage program in hidradenitis suppurativa, extending cash runway into the second half of 2029.
Analysis · SYRE · Life Sciences
Spyre Therapeutics finalized terms of a $350 million public offering of 4,117,648 shares at $85.00 per share, a 4.5% discount to the last reported sale price of $93.19 on October 2, 2026. The company will receive approximately $328.7 million in net proceeds after underwriting discounts of $5.10 per share and estimated expenses. This capital raise extends Spyre's cash runway into the second half of 2029 and funds Phase 3 readiness for its immunology pipeline, including a new SPY072 program in hidradenitis suppurativa. New investors face immediate dilution of $71.51 per share relative to pro forma as-adjusted net tangible book value of $13.49 per share. The offering is expected to close October 7, 2026, with a 60-day lock-up on executive officers and directors.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3715 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SYRE was trading at $80.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1B. The 52-week trading range was $15.86 to $110.18. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.